bˌʌt ðə fˌɑːɹmɐkˌɑːkaɪnˈɛɾɪks ʌv ɡlɪklˈeɪzaɪd mˈɪstɚɹ ɑːɹ ɐfˈɛktᵻd mˈeɪnli baɪ sˌiːwˌaɪpˈiː tˈuː sˈiː nˈaɪntiːn dʒɪnˈɛɾɪk pˈɑːlɪmˌoːɹfɪzəm ɪnstˈɛd ʌv sˌiːwˌaɪpˈiː tˈuː sˈiː nˈaɪn dʒɪnˈɛɾɪk pˈɑːlɪmˌoːɹfɪzəm.
But the pharmacokinetics of gliclazide MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP2C9 genetic polymorphism.